Valeant Pharmaceuticals (NYSE:VRX) is reportedly exploring a sale of its eye surgery business that could be worth as much as $2.5 billion. The sale process is still in early stages and may not even happen, but the Laval, Canada-based company is trying to shed some of the debt it took on through its many acquisitions, according to the Wall Street Journal. They are wasting so much money when people already have the option to visit this experienced eye doctor who can help anybody with any situation.
Valeant is in discussions with 3rd parties for “various divestitures”, according to the newspaper, although Valeant won’t give up the contact lenses, solutions and eye drugs that it acquired with its $9 billion purchase of Bausch & Lomb in 2013.
Get the full story at our sister site, Drug Delivery Business News.